What is happening? Are the current acceptance criteria for therapeutic plasma adequate?

Transfusion and Apheresis Science

Volumn 31, Issue 1, 2004, Pages 67-73

  Seghatchian, Jerard ^a  

^a 50 Primeroe Hill Road   (United Kingdom)

Author keywords

Efficacy; Fresh frozen plasma; Methylene blue; Quality requirement; Safety; Solvent detergent; Transfusion reactions

Indexed keywords

BLOOD CLOTTING FACTOR; DETERGENT; FRESH FROZEN PLASMA; METHYLENE BLUE; PROTEINASE INHIBITOR; RIBOFLAVIN;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD GROUP ABO SYSTEM; BLOOD STORAGE; BLOOD TRANSFUSION; CELL SEPARATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; ILLUMINATION; LEUKOCYTE; LIVER DISEASE; PLASMAPHERESIS; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SCREENING; THROMBOCYTE; THROMBOSIS; ULTRAVIOLET RADIATION; VIRAL CONTAMINATION; VIRUS INACTIVATION; VIRUS INFECTION;

EID: 3843070949     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2004.04.002     Document Type: Article

References (24)

1. Lambrecht B., Mohr H., Knuver-Hopf J., Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang. 60:1991;207-213
2. Seghatchian J., Krailadsiri P. The quality of methylene blue light treated FFP and cryoprecipitate. Transfus. Apheresis. Sci. 25:2001;227-231
3. Williamson L.M., Cardigan R., Prowse C.V. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety (review). Transfusion. 43:2003;322-1329
4. Seghatchian J., Allain J.P. Current strategies for the prevision of safer plasma and its derivatives: an update. Transfu. Apheres. Sci. 25:2001;185-187
5. Pennington J., Taylor G.P., Sutherland J., Davis R.E., Seghatchian J., Allain J.P., et al. Persistence of HTLV-1 in blood components after leukocyte depletion. Blood. 100(2):2002;677-681
6. Wagner S.J. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus. Med. Rev. 16:2002;61-66
7. Krailadsiri P., Seghatchian J. Residual red cell and platelet contents in WBC-reduced plasma measured by a novel flowcytometric method. Transfus. Apheres. Sci. 24:2001;270-286
8. Seghatchian J. Universal leucodepletion: an overview of some unreserved issues and the highlights of lessons learned. Transfus. Apheres. Sci. 29:2003;105-117
9. Burnouf T., Kappelsberger C., Frank K., Burkhardt T. Residual cell content in plasma produced by three centrifugal apheresis procedures. Transfusion. 43:2003;1522-1526
10. Solheim B.G., Flesland O., Brosstad F., Mollne T.E., Seghatchian J. Improved preservation of coagulation factors after prestorage leucocyte depletion of whole blood. Transfus. Apheres. Sci. 29:2003;133-146
11. Trindade H., Carvalho H., Sousa G., Machado Caetano J.A., Seghatchian J. Filtration induces changes in activity states and leucocyte populations. Transfus. Apheres. Sci. 28:2003;319-327
12. De la Rubia J., Arriaga F., Linares D. Role of methylene blue-treated or fresh plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br. J. Haematol. 114:2001;721-723
13. Seghatchian J. The quality of clinical FFP, cryoprecipitate, cryosupernatant-derived from single donor apheresis procedures and random donations collected in BAT system: assessment of the quality states of FVIII, contact activation, microvesicle content and cytokines. Transfus. Sci. 18:1997;115-118
14. Hellstem P., Haubelt H. Manufacture and composition of fresh frozen plasma and virus inactivated therapeutic plasma preparations: correlations between composition and therapeutic efficacy. Thromb. Res. 107:2002;83-88
15. Heiden M., Seitez R. Quality of therapeutic plasma: requirements for marketing authorization. Thromb. Res. 107:2002;47-51
16. Sazama K. Non-viral, non-hemolytic adverse effects of transfusion. Transfus. Apheresis. Sci. 29:2003;131-132
17. Simonson A.C., Sorensen H. Clinical tolerance of methylene blue virus-inactivated plasma. Vox Sang. 77:1999;210-217
18. AuBuchon J.P., Pickard C., Herschel L.O., Corner J.P., Lee E. Removal of methylene blue from plasma via an adsorbent filter. Vox Sang. 74:1998;1-6
19. Wieding J.U., Rathgeber J., Zemker D., Pohl U., Kohler M. Prospective, randomised and controlled study on solvent /detergent versus methylene blue light virus-inactivated plasma. Transfusion. (SV):1999;23
20. Aguzzi A., Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell. 16:2004;313-327
21. Dzik W.H. Apoptosis, TGF-beta and transfusion-related immunosuppression: biological versus clinical effects. Transfus. Apheres. Sci. 29:2003;127-129
22. Seghatchian J. A novel method for the assessment of pro- and anti-coagulant properties of platelet-derived microvesicle and its usefulness for quality of platelet haemostatic function. Transfus. Apheres. Sci. 20:2003;119-125
23. Seghatchia J., De Sousa G. Blood cell apoptosis/necrosis: some laboratory and clinical aspects. Ann NO Y Sci. 1010:2003;S40-S47
24. Depasse F, Seghatchian J, Sensebe L, Andreu G, Samama MM. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. Transfusion 2004; submitted